ObjectiveGI Partnering with ARcare to Provide Advanced Diagnostics and Cutting-Edge Treatment Options for Patients

The clinically integrated research platform will provide thousands of patients with chronic digestive health conditions in the ARcare network access to advanced care options. NASHVILLE, TN, September 1, 2020 – ObjectiveGI, the integrated research and technology services platform company, announced today it has partnered with ARcare, a federally qualified health care system in Arkansas, Kentucky and Mississippi, to bring advanced diagnostics ... Read More

International NASH Day – Bringing the disease into focus

Today, June 12, marks the third annual International NASH Day. The NASH Education Program started this campaign in 2018 to raise awareness and urgency around nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH). The Global Liver Institute continues to spearhead a consortium of patient advocacy organizations, as well as medical and professional groups, to shine ... Read More

Our gut microbes influence our reactions to medications, new research shows.

A number of studies have found that certain strains of bacteria within a patient’s microbiome can impact their body’s response to medication – in both positive and negative ways. Read more to learn about these discoveries.

Evidence in favor of blood testing shows new technology surpassing anticipated milestones.

Despite past fraudulent claims about this technology from Theranos – the now-infamous and defunct healthcare company – blood testing capabilities are fast outpacing previous predictions in the medical field. Take a look at this FierceBiotech article to learn more.

Hydrogel pill for overweight or obese patients approved by FDA.

In 2019, the FDA approved the Gelesis100 oral hydrogel pill therapy for weight management. This capsule induces a feeling of fullness to help patients control their hunger without the drawback of added calories. Read more about this first-of-its-kind hydrogel pill therapy.

ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures

Contacts:Colleen Hoke, ObjectiveGI colleen.hoke@objectivegi.com Jillian Hammell, Crowley Webbjillian.hammell@crowleywebb.com716.856.2932 x237 ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic NASHVILLE, TN, December 20, 2019 – ObjectiveGI, the integrated research and technology services platform company, announced ... Read More

A study from UT Southwestern identifies a protein in the gut linked to weight gain.

Dr. Lora Hooper and her colleagues found that the body’s metabolic rhythm is determined by gut bacteria: microbes activate the protein histone deacetylase 3 (HDAC3), which then interacts with the body’s metabolism to adjust fat absorption. The more fat consumed, the more HDAC3 tells the body to absorb this fat, which can lead to obesity.

MIT researchers recommend a new conceptual framework for stool donor selection.

To decrease the number of false-negative outcomes in fecal microbiota transplantation (FMT) trials, Dr. Eric J. Alm and colleagues propose a more rational approach for selection strategies.

Scientists believe there is a link between childhood obesity and gut bacteria.

After reviewing studies from the past decade, Dr. Hariom Yadav and his colleagues at Wake Forest Baptist Health published new information to support their theory that certain microbes in the gut can cause childhood obesity.

Today at ACG 2019 Annual Scientific Meeting

We’re excited to be part of the American College of Gastroenterology 2019 Annual Scientific Meeting. Come see us at booth 1520 and learn how we’re transforming care and improving patient outcomes through our GI partnerships focused on clinical trials and delivering new science at the point of care.  At the ACG 2019 Annual Scientific Meeting, let’s discuss how we can ... Read More

Visit us at ACG 2019!

Come visit with our ObjectiveGI team at the American College of Gastroenterology’s 2019 Annual Scientific Meeting, October 25–30 in San Antonio, TX.  Learn how we’re transforming patient care. We’ll be at booth 1520 in the Henry B. González Convention Center, ready to connect with GI specialists to discuss creating premier clinical research centers-of-excellence focused on developing new therapies. See how ... Read More

Studies Show Increased Presence of Concurrent Type 2 Diabetes and NAFLD

An analysis of 80 worldwide studies shows the ever-growing prevalence of patients with both type two diabetes and nonalcoholic fatty liver disease. This prevalence varies in different regions of the globe.

NASH Leads Liver Disease “Economic Tsunami” in the US

A white paper presented by the University of Oxford’s visiting professor of hepatology, Dr. Stephen A. Harrison, examines the economic impact of the liver disease epidemic on the US healthcare system.

Phase II clinical trial shows promise for type 2 diabetes

Fantastic news out of Amsterdam University Medical Center! A phase II study has reported duodenal mucosal resurfacing has promising results for type 2 diabetes patients, showing lasting improvements for insulin resistance markers and glycemic control – all without bariatric surgery.

Combined tests help identify NASH-related fibrosis

Researchers at Newcastle University in the UK found that Fibrosis-4 indexes coupled with enhanced liver fibrosis tests can identify NASH-related advanced fibrosis while reducing indeterminate results rate. Take a look at their compelling study.

Studies show microbiome may contribute to all immune-related diseases

Multiple studies suggest that the gut microbiome likely contributes to all diseases caused by a dysregulation of the immune system – including obesity, diabetes, and NASH.

New ADA Recommendation

The American Diabetes Association is now recommending screening for liver fibrosis in patients with type 2 diabetes suspected of having nonalcoholic fatty liver disease.

Weight loss continues to be associated with clinically meaningful improvements

Weight loss continues to be associated with clinically meaningful improvements in biomarkers of nonalcoholic fatty liver disease.

New research aimed at developing a first-in-class dual agonist

New research aimed at developing a first-in-class dual agonist that targets all three key drivers of NASH – steatosis, inflammation, and fibrosis.

ObjectiveGI Collaborates with Clinical Research IO

ObjectiveGI Collaborates with Clinical Research IO to Launch eSource Direct Data Capture Research Capabilities at the Point-of-Care

New drug for treating fatty liver disease

A new drug for treating fatty liver disease is currently being reviewed by the FDA.

weight loss with ESG

Landmark research shows 15% sustainable weight loss with ESG which is associated with improvement in NASH, diabetes and cardiovascular disease.

Routine screening for NAFLD

Routine screening for NAFLD is recommended for type 2 diabetes patients.

cardiovascular disease risk in patients

There is evidence of cardiovascular disease risk in patients with NAFLD and type 2 diabetes.

Gut microbes eat our medication.

Fascinating early work on the role of the microbiome and drug metabolism.

18 million patients with NAFLD

A telling study of 18 million patients with NAFLD, and the associated risk of cirrhosis.